Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
This followed the agencys April 2026 removal of BPC-157 from Category 2 after original nominations were withdrawn, shifting the substance out of the significant safety risk designation but leaving it in regulatory limboneither explicitly barred nor authorized for 503A compounding
Human clinical data is limited
It may be found that BPC 157 participates in ocular control (i.e., BPC 157 counteracted L-NAME-miosis and atropine-mydriasis) (Kokot et al., 2016)
B12 serum levels and IFA test
The product appears under general medical supply or sterile diluent listings
US$ 28.59
US$ 27.92
US$ 20.06
US$ 20.32
US$ 20.73
